灵康药业
(603669)
| 流通市值：35.70亿 | | | 总市值：35.70亿 |
| 流通股本：7.21亿 | | | 总股本：7.21亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 256,883,646.75 | 254,087,208.94 | 123,225,366.34 | 323,670,765.11 |
| 应收票据及应收账款 | 264,549,505.7 | 243,202,284.71 | 60,917,763.91 | 80,389,653.46 |
| 应收账款 | 264,549,505.7 | 243,202,284.71 | 60,917,763.91 | 80,389,653.46 |
| 应收款项融资 | - | - | - | 898,080 |
| 预付款项 | 1,502,751.79 | 17,934,665.05 | 15,249,167.71 | 7,268,295.47 |
| 其他应收款合计 | 4,890,203.2 | 4,692,354.82 | 10,081,012.97 | 5,258,687.48 |
| 存货 | 23,300,966.11 | 27,879,613.88 | 61,483,050.15 | 37,525,751.84 |
| 其他流动资产 | 9,785,871.31 | 7,592,358.81 | 14,950,463.35 | 14,708,653.97 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 574,661,138.37 | 586,610,563.8 | 495,170,740.5 | 725,113,933.72 |
| 非流动资产: | | | | |
| 长期股权投资 | 14,584,608.81 | 17,939,111.32 | 28,760,795.15 | 32,848,981.5 |
| 其他权益工具投资 | 57,731,807.71 | 57,731,807.71 | 60,000,000 | 60,000,000 |
| 投资性房地产 | 6,916,376.64 | 7,024,151.54 | 8,028,544.84 | 15,827,614.18 |
| 固定资产 | 228,878,107.24 | 234,314,219.59 | 249,064,032.88 | 248,849,724.18 |
| 在建工程 | 228,223,631.76 | 228,223,631.76 | 231,777,658.08 | 231,519,859.91 |
| 使用权资产 | 6,665,964.81 | 7,131,032.13 | 7,596,099.45 | 8,061,166.77 |
| 无形资产 | 99,182,264.51 | 100,901,478.24 | 104,683,545.22 | 104,852,362.83 |
| 长期待摊费用 | 13,682,035.45 | 14,233,091.46 | 14,820,324.05 | 15,571,390.1 |
| 递延所得税资产 | - | - | 2,549,079.56 | 2,643,318.26 |
| 其他非流动资产 | 905,500 | 1,224,500 | 3,201,100 | 2,784,425 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 656,770,296.93 | 668,723,023.75 | 710,481,179.23 | 722,958,842.73 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,231,431,435.3 | 1,255,333,587.55 | 1,205,651,919.73 | 1,448,072,776.45 |
| 流动负债: | | | | |
| 短期借款 | - | - | - | 17,359,971.21 |
| 应付票据及应付账款 | 116,250,867.7 | 109,561,545.54 | 61,336,478.54 | 51,829,026.43 |
| 其中：应付票据 | 14,086,726.1 | 16,031,280.1 | 6,715,515.2 | 8,978,661.2 |
| 应付账款 | 102,164,141.6 | 93,530,265.44 | 54,620,963.34 | 42,850,365.23 |
| 预收款项 | 332,755.75 | 198,758.68 | 552,798.17 | 252,147.56 |
| 合同负债 | 9,688,056.38 | 6,681,668.57 | 7,620,462.77 | 9,763,280.66 |
| 应付职工薪酬 | 2,715,592.09 | 8,205,429.32 | 2,999,705.74 | 3,012,105.93 |
| 应交税费 | 3,735,202.63 | 12,727,406.13 | 1,263,383.46 | 1,190,093.41 |
| 其他应付款合计 | 72,055,132.57 | 77,202,160.99 | 5,092,013.41 | 4,683,411.84 |
| 一年内到期的非流动负债 | 2,247,304.29 | 2,189,451.78 | 7,005,670.17 | 5,569,400.99 |
| 其他流动负债 | 2,185,183.32 | 2,547,790.54 | 1,861,638.03 | 2,160,306.36 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 209,210,094.73 | 219,314,211.55 | 87,732,150.29 | 95,819,744.39 |
| 非流动负债: | | | | |
| 应付债券 | 262,994,537.52 | 257,991,407.31 | 251,975,356.88 | 452,851,099.79 |
| 租赁负债 | 4,074,716.22 | 4,074,716.22 | 5,843,096.39 | 5,843,096.39 |
| 递延收益 | 2,340,777.59 | 2,410,683.5 | 2,480,589.41 | 2,550,495.32 |
| 递延所得税负债 | 1,666,491.2 | 1,782,758.03 | 1,898,394.72 | 2,015,291.69 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 271,076,522.53 | 266,259,565.06 | 262,197,437.4 | 463,259,983.19 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 480,286,617.26 | 485,573,776.61 | 349,929,587.69 | 559,079,727.58 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 721,244,755 | 721,244,005 | 721,240,880 | 721,239,005 |
| 其他权益工具 | 60,479,775.85 | 60,481,210.28 | 60,486,347.92 | 94,090,676.22 |
| 资本公积 | 262,652,509.36 | 262,645,577.37 | 262,463,836.51 | 255,642,400.72 |
| 减:库存股 | 110,019,822.2 | 110,019,822.2 | 110,019,565.79 | 110,019,565.79 |
| 其他综合收益 | -2,268,192.29 | -2,268,192.29 | - | - |
| 盈余公积 | 144,362,187.9 | 144,362,187.9 | 144,362,187.9 | 144,362,187.9 |
| 未分配利润 | -325,306,395.58 | -306,685,155.12 | -222,811,354.5 | -216,321,655.18 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 751,144,818.04 | 769,759,810.94 | 855,722,332.04 | 888,993,048.87 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 751,144,818.04 | 769,759,810.94 | 855,722,332.04 | 888,993,048.87 |
| 负债和股东权益合计 | 1,231,431,435.3 | 1,255,333,587.55 | 1,205,651,919.73 | 1,448,072,776.45 |
| 公告日期 | 2025-04-26 | 2025-04-19 | 2024-10-31 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |